COMMUNIQUÉS West-GlobeNewswire

Le docteur William J. Foster se joint à l’équipe d’Altasciences à titre de chercheur principal

06/09/2018 - 14:12

LAVAL, Québec, 06 sept. 2018 (GLOBE NEWSWIRE) -- Altasciences est fière de souhaiter la bienvenue au docteur William J. Foster, M.D., Ph. D., FRCSC, qui se joint à l’équipe à titre de chercheur principal et de [...]

CLS Holdings USA Announces Increased Sales Growth at Oasis Cannabis

06/09/2018 - 14:06

Entering Second Full Year of Legalized Adult Use in Las Vegas, Nevada LAS VEGAS, Sept. 06, 2018 (GLOBE NEWSWIRE) -- CLS Holdings USA, Inc. (OTCQB: CLSH) “CLS,” a diversified cannabis company operating as Cannabis Life [...]

Matinas BioPharma Announces Appointment of Industry Leader Patrick G. LePore to Board of Directors

06/09/2018 - 14:01

BEDMINSTER, N.J., Sept. 06, 2018 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER:MTNB), a clinical-stage biopharmaceutical company focused on enabling targeted intracellular delivery of life-changing [...]

HempAmericana Commences Initial CBD Oil Production in $2.1B CBD Market

06/09/2018 - 14:00

NEW YORK, Sept. 06, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE-- HempAmericana, Inc. (OTC: HMPQ) (“HempAmericana” or the “Company”) is thrilled to announce the commencement of initial CBD Oil production at its principal [...]

Forty Seven Inc. to Present at the Morgan Stanley 16th Annual Global Healthcare Conference

06/09/2018 - 14:00

MENLO PARK, Calif., Sept. 06, 2018 (GLOBE NEWSWIRE) -- Forty Seven Inc. (NASDAQ:FTSV), a clinical-stage, immuno-oncology company focused on developing therapies to activate macrophages in the fight against cancer, today [...]

Evelo Biosciences to Present at the Morgan Stanley 16th Annual Global Healthcare Conference

06/09/2018 - 14:00

CAMBRIDGE, Mass., Sept. 06, 2018 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO) (“Evelo”), a clinical stage biotechnology company developing monoclonal microbials designed to act on the gut-body network for [...]

Chiesi Partnership with Durham Bulls Closes Season with $15,000 to Area Nonprofits

06/09/2018 - 14:00

The company’s presenting strikeout partnership is a homerun for three local charities CARY, N.C., Sept. 06, 2018 (GLOBE NEWSWIRE) -- Leading into the first pitch at the Durham Bulls August 31 home game against the [...]

Melinta Therapeutics to Host Meetings at the Morgan Stanley 16th Annual Global Healthcare Conference

06/09/2018 - 14:00

NEW HAVEN, Conn., Sept. 06, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat serious bacterial [...]

AMAG Pharmaceuticals Pays Off $475 Million of Senior Secured Notes

06/09/2018 - 14:00

Early Retirement of more than $800 million in debt since mid-2017 significantly strengthens balance sheet WALTHAM, Mass., Sept. 06, 2018 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that [...]

Bespoke Extracts and Hip Hop Mega-Celebrity Soulja Boy to Collaborate on Development of Co-Branded CBD Product Line

06/09/2018 - 14:00

SUNNY ISLES, Fla., Sept. 06, 2018 (GLOBE NEWSWIRE) -- Bespoke Extracts, Inc. (OTCQB: BSPK), producer of high quality, great tasting, hemp-derived CBD products, today announced that Grammy-nominated, American Hip Hop [...]

GBT Brings Together Sickle Cell Disease Influencers at 7th Annual Sickle Cell Disease (SCD) Therapeutics Conference

06/09/2018 - 14:00

Healthcare Providers, Patient Advocates and Policy Makers Will Discuss Issues Impacting SCD Community During National SCD Awareness Month Livestream of Conference Will Be Available through Collaboration with Sickle Cell [...]

Tower One September Update

06/09/2018 - 14:00

VANCOUVER, British Columbia, Sept. 06, 2018 (GLOBE NEWSWIRE) -- Tower One Wireless Corp (CSE: TO) (OTCQB: TOWTF) (Frankfurt: 1P3N) (“Tower One” or the “Company”) announces a comprehensive update on recent company [...]

Soleno Therapeutics Announces Expansion of Ongoing Phase III Trial of DCCR in Prader-Willi Syndrome to Include Younger Patients

06/09/2018 - 14:00

Amendment Lowers Minimum Age Inclusion Criteria to Four Years, from Eight Years, to Better Reflect Demographics of PWS Population Top-line Data from Phase III Trial Expected in First Half of 2019 REDWOOD CITY, Calif., [...]

Integrated Cannabis Company, Inc. Provides Corporate Update

06/09/2018 - 14:00

THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, Sept. 06, 2018 (GLOBE NEWSWIRE) -- Integrated Cannabis Company, Inc. (CSE: ICAN, [...]

RedHill Biopharma Announces Advancement to Second Stage of Phase IIa Study with YELIVA® for Cholangiocarcinoma

06/09/2018 - 14:00

The first stage of the Phase IIa study with YELIVA ® for advanced cholangiocarcinoma (bile duct cancer), a highly lethal malignancy, achieved its pre-specified efficacy goal, and the study can therefore continue to its [...]

Atara Biotherapeutics and Moffitt Cancer Center Announce Strategic Collaboration to Develop Next-Generation CAR T Immunotherapies

06/09/2018 - 13:30

Focus on multi-targeted CAR T immunotherapies for patients with acute myelogenous leukemia (AML) and B-cell malignancies Collaboration includes novel CAR T targeting and signaling domains designed to optimize T cell [...]

Specialty Renal Products Announces $3 Million Series A Financing

06/09/2018 - 13:30

SOUTH ORANGE, NJ, Sept. 06, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Specialty Renal Products, Inc. (SRP), a private medical device company focused on the development of products for patients with renal disease, [...]

Metacrine Appoints Hubert Chen, M.D. as Chief Medical Officer and Andrew Guggenhime to the Board of Directors

06/09/2018 - 13:30

SAN DIEGO, Sept. 06, 2018 (GLOBE NEWSWIRE) -- Metacrine, Inc., a biotechnology company developing therapies to benefit patients with liver and gastrointestinal diseases (GI), today announced the appointment of Hubert C [...]

Checkpoint Therapeutics Announces Encouraging Safety and Efficacy Data from Phase 1/2 Clinical Trial of EGFR Inhibitor CK-101

06/09/2018 - 13:30

6 of 8 pts (75%) ORR in treatment-naïve EGFR mutation-positive NSCLC patients Well-tolerated with unremarkable safety profile; No DLTs or related SAEs Phase 3 trial in treatment-naïve EGFR mutation-positive NSCLC [...]